Program
Oxaliplatin
Also written as “oxaliplatin”, “Oxaliplatin (SR96669)” and “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”.
Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Rectal Neoplasms · Carcinoma, Hepatocellular, led by 9 companies.
Drug pageOxaliplatin: every studyMany companies study it; this page follows only the 66 they lead. All 854 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 360 open or running | phase 4since Aug 10, 2005 | Jan 6, 2001 | none ahead |
| Hoffmann-La Rocheits history only | 201 open or running | phase 4since Dec 18, 2007 | Sep 15, 2003 | Mar 22, 2027phase 1 · NCT06624085 |
| Prologue Research Internationalits history only | 30 open or running | phase 3since Jun 5, 2003 | May 6, 2001 | none ahead |
| Pfizerits history only | 21 open or running | phase 3since Oct 5, 2020 | Nov 6, 2007 | none ahead |
| Criterium | 10 open or running | phase 2since Sep 24, 2019 | Sep 24, 2019 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Sep 27, 2007 | Sep 27, 2007 | none ahead |
| Nang Kuang Pharmaceuticalits history only | 10 open or running | phase 2since Mar 28, 2011 | Mar 28, 2011 | none ahead |
| NovoCureits history only | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| Sirtex Medicalits history only | 10 open or running | phase 3since Aug 13, 2008 | Aug 13, 2008 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, AbbVie, Zai Lab, Amgen, Bristol-Myers Squibb, Regeneron Pharmaceuticals and Yakult Honsha.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Criterium only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2019First study: phase 2 study in Colorectal Cancer MetastaticFirst studyNCT04169347 · 27 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Criterium leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04169347Colorectal Cancer Metastatic · United States | 2 | UNKNOWN | Dec 2024 | 27 |
How it is read
Names in the registry
- “Oxaliplatin”, 51 entries
- “oxaliplatin”, 20 entries
- “Oxaliplatin (SR96669)”, 3 entries
- “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
- “OXALIPLATIN”, 3 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 35 studies
- Stomach Neoplasms, 16 studies
- Pancreatic Neoplasms, 7 studies
- Rectal Neoplasms, 6 studies
- Carcinoma, Hepatocellular, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.